PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143381
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143381
Gene Fusion Testing market size was valued at US$ 830.1 Million in 2025, expanding at a CAGR of 13.1% from 2026 to 2033.
The global Gene Fusion Testing market refers to that part of molecular diagnostics and precision medicine that was developed specifically for testing genetic mutations, including gene fusions, occurring during the process of various diseases' development, including oncology. A gene translocation test is used for identifying protein mutations that result in the development of cancer. As the demand for new technologies has been constantly rising, the global Gene Fusion Testing market has become an integral part of the field of precision medicine, allowing for creating a personalized approach to treating patients based on their genetic background.
The global Gene Fusion Testing market represents a key field for personalizing cancer therapy on the basis of information about genetic abnormalities. There are several technologies that are used in the global Gene Fusion Testing market for the purpose of detecting gene translocations in cases of different kinds of cancer, such as NGS (next generation sequencing), FISH (fluorescence in situ hybridization), and PCR (polymerase chain reaction). These technologies enhance gene fusion detection, supporting accurate diagnosis and targeted cancer treatment decision.
Gene Fusion Testing Market- Market Dynamics
Increasing Cancer Disease Prevalence to Accelerate Market Expansion
The increasing prevalence of cancer is driving demand for gene fusion testing because of the growing number of cancer patients, who increase the need for accurate molecular tests for actionable mutations and for treatment planning in each particular case. For example, in March 2026, according to Eurostat, cancer was the second most common cause of deaths in the EU, and there were about 1.16 million cases (23.9%) out of all deaths in this period. The cancer cases were more common among the elder population, as the standardized death rate was 936.0 cases per 100,000 inhabitants over 65 years of age, while the death rate among the younger population was 62.9 per 100,000 inhabitants under 65 years of age. There were 233.1 cases of cancer per 100,000 inhabitants in the total EU standardized death rate from cancer, while the death rate among males was 302.8 cases and among females was 183.7 cases per 100,000 inhabitants. These trends are expected to accelerate demand for gene fusion testing in cancer diagnosis and treatment planning.
The Global Gene Fusion Testing market is segmented on the basis of Category, Technology, Indication, End User, and Region.
Based on technology, Polymerase Chain Reaction (PCR) holds an important position in the Gene Fusion Testing market due to greater sensitivity and quick turnaround time as well as greater applications in the detection of gene fusions for screening and molecular profiling of cancer patients. For instance, in February 2025, according to a PLOS ONE (Org.), the high-frequency PCR testing method was used for about 3,421 healthcare workers and in around 285,000 oral swab samples. Unvaccinated healthcare workers were mandated to do PCR tests twice a week; all healthcare workers were mandated to do PCR tests twice a week, leading to a total of 17,940 PCR tests and 17,479 in a month at a German care facility conducting continuous surveillance of SARS-CoV-2. These technologies facilitate reliable, efficient, and quick detection of clinically actionable gene fusion events.
Gene Fusion Testing Market- Geographical Insights
Based on region, Asia-Pacific is projected to be the growing region in the global Gene Fusion Testing market due to the rising presence of diagnostic companies and investments in molecular diagnostics. For example, in June 2026, the India Brand Equity Foundation (IBEF) stated that India's market for diagnostic devices will achieve ($6,000 million) in 2027, as compared to or ($4,000 million) in CY23. There is significant growth in the demand, which offers an opportunity to diagnostic companies to increase their presence in the Indian region. Moreover, India's market for medical devices is forecasted to reach from ($15,200 million) in 2025 to ($50,100 million) in 2030 because of the growing demand for healthcare, hospital infrastructure, and insurance coverage. This trend is expected to strengthen diagnostic capabilities and accelerate gene fusion testing adoption across Asia-Pacific.
Singapore Gene Fusion Testing Market - Country Insights
Singapore is developing rapid routes towards approving and regulating companion and molecular diagnostics, and this ensures faster time-to-market and increased adoption of innovations. In August 2025, according to the Singapore Economic Development Board (Gov), Singapore's ecosystem of companies, either local or global, amounts to a total of more than 400 companies employing over 17,000 individuals, and the topmost MedTech companies of the world include the top 30 MNCs, which are operating in Singapore. These MedTech companies manufacture a total value of more than S$19 billion SGD of high-value medical devices per year, which includes, among others, contact lenses and cardiac implants, and one of the most amazing facts, which is indeed amazing, is that out of the total 30 MNCs, more than 20 companies set up R&D centres in Singapore.
And the nation's National Precision Medicine Initiative and SG100K Programme expect Singapore to conduct a detailed analysis of large data points like lifestyles, clinical factors, genomics, and environmental factors of around ten per cent of the total population of Singapore up to 2031, and all of the 100,000 Singaporeans will undergo genomic sequencing and analysis. All of these capabilities go on to facilitate the development of advanced diagnostic technologies, which include AI-based diagnostics that process medical images faster and more accurately, cancer-risk modelling, congenital hearing loss risk prediction, and others.
Technological innovations, investments, and finance are key drivers that propel the worldwide Gene Fusion Testing market forward. There are some well-known companies like Roche, Guardant Health, Illumina, Biocartis, and Amoy Diagnostics that are contributing to technology development in order to drive the growth of the global market of gene fusion testing, along with the use of the above-mentioned technology to conduct gene fusion testing. In May 2026, Roche signed an agreement with PathAI, buying the company for $750 million in cash upfront and $300 million in milestones, and this will help Roche be a better competitor in the industry of digital pathology and companion diagnostics using artificial intelligence. These strategic developments are expected to accelerate innovation and expand gene fusion testing capabilities.
In July 2025, Amoy Diagnostics, Riken Genesis, and Precision Medicine Asia have announced that the AmoyDx(R) Pan Lung Cancer PCR Panel is an approved companion diagnostic for amivantamab and lazertinib in Japan. It is a complete test kit for screening of mutations in various genes like EGFR, ALK, ROS1, KRAS, BRAF, HER2, RET, MET, NTRK1, NTRK2, and NTRK3, including ALK, ROS1, and RET gene fusions.